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1. Introduction  
1.1 Challenges of diagnosis and treatment for pancreatic cancer 
As one of the deadliest human malignancies, pancreatic cancer is commonly diagnosed at an 
advanced stage, resulting in 5-years relative survival of 9% only (Siegel et al., 2019). For 
pancreatic cancer, radical surgery may be the only curative treatment so far, and delineation of 
tumor margins is essential for radical surgery which remains challenging in practice(DeVita 
VT, 2005). Moreover, patients with pancreatic cancer usually bear small metastatic disease that 
is hardly to be detected by traditional diagnostic methods. Surgeons can only depend on visual 
and tactile sensation to determine the boundaries of resection along with traditional 
preoperative radiation imaging or magnetic resonance imaging modalities. Clinical imaging 
modalities have a great spatial resolution but they cannot be used intraoperatively. 
Intraoperative biopsies could sometimes be used for monitoring the tumor margins, however it 
is impractical for tumor margin delineation. Consequently, it was reported that as many as 80% 
of pancreatic resections are not considered radical resection due to positive surgical margin 
(less than 1 mm from the tumor margin), which remains a risky factor for postoperative 
recurrence (Markov et al., 2016; Strobel et al., 2017). Therefore, new diagnostic strategies for 
pancreatic cancer are urgently required. 
1.2 Near-infrared fluorescent molecular imaging for pancreatic cancer 
Near-infrared (NIR) fluorescent molecular imaging can overcome the above-mentioned 
challenges for intraoperative diagnosis of pancreatic cancer.  
1.2.1. NIR fluorescent molecular imaging 
Fluorescent molecular imaging has many advantages compared with traditional clinical 
imaging modalities. Firstly, by using targeted tracers, the detection of tumor lesions has high 
sensitivity and specificity. Tumor-selective molecules on the cell surface are the main targets 
for NIR fluorescent molecular imaging, and the targeted molecules include cell receptors and 
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adhesion proteins (Ogawa et al., 2009). Additionally, due to its physical properties, NIR 
Fluorescence allows noninvasive visualization of tumors with several millimeters in depth, 
while no ionizing radiation is used. (Frangioni, 2008; Mahmood and Weissleder, 2003). The 
advent of fluorescent molecular tomography (FMT) demonstrates the ability for quantification, 
and it is reported to be able to image to a depth of 10 cm (Ntziachristos, 2006). Furthermore, 
the currently used NIR fluorescent tracer with emission wavelengths between 700 and 2500 nm 
has led to a low background (auto)fluorescence (Fig.1-1) (Frangioni, 2003; Weissleder and 
Ntziachristos, 2003).  
 
(Fig.1-1 Diagram of light spectrum, the picture was downloaded from the website below 
http://www.processsensors.com/appbl_II/?p=2998) 
1.2.2. NIR fluorescent molecular imaging probes 
Of the organic probes, there are mainly non-targeted NIR fluorescent probes and targeted 
NIR fluorescent probes in use.  
Non-targeted organic NIR fluorescent probes 
Of the non-targeted organic NIR fluorescent probes, indocyanine green (ICG) has been 
developed commercially for more than 50 years and widely used in clinical application. 
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However, ICG as a non-targeted NIR fluorescent probe yields low signal-to-noise ratio (Gioux 
et al., 2010). The hydrophobicity, photosensitivity and low tumor cell specificity limit the wide 
use of these small molecular probes in clinical cancer diagnosis and fluorescent tumor guidance 
in the operation, and further highlight the importance of designing and synthesizing new tumor 
specific NIR fluorescent probes (RP., 2002.). 
Targeted organic NIR fluorescent probes 
The target organic fluorescence probe is conjugating the fluorescence probe with a ligand 
that can bind to a specific molecule on the cell surface. The coupling fluorescent probe can be 
bound to and remain at the target site, while the non-binding fluorescent probe is removed in 
the blood circulation. As cancers have selective expression of some molecules on the cancer 
cell surface or in the tumor microenvironment, this method is most valuable for tumor specific 
imaging. 
Ligands can be small molecules, peptides, proteins, and antibodies. The fluorescent groups 
that can be combined now include IRDye800CW, Cy5.5, etc. Although FDA has not approved 
these relevant probes for clinical application, relevant clinical experiments have been carried 
out (Whitley et al., 2016). 
The IRDye800CW dye carries an NHS ester reactive group and can be conjugated with 
high molecular weight (45-200 kDa) proteins. The spectral properties with an absorption and 
emission maximum of 774 nm and 789 nm separately are comparable to FMT imager with 800 
nm channel. The NIR fluorescent probe of IRDye800CW has been proven with high stability 
and low toxicity (Kovar et al., 2007). 
Inorganic NIR fluorescent probes  
Inorganic NIR fluorescent probes are mainly composed of quantum dots (QDs) (Bharali 
and Mousa, 2010; Nurunnabi et al., 2010) and other nanoparticles (NPs) (He et al., 2010; Wang 
et al., 2005). While for the non-organic probes, high cytotoxicity has limited their biological 
applications. 
The advantages of NIR fluorescent molecular imaging   
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First, NIR fluorescent molecular imaging is a non-invasive optical imaging modality. NIR 
fluorescence can penetrate several millimeters in tissue, without ionizing radiation allowing 
non-invasive visualization of tumors. FMT was reported to be able to image into a depth of 10 
cm (Ntziachristos, 2006). While the current predominant clinical imaging system has 
disadvantages of not only radioactive risks but also low specificity and sensitivity for diagnosis 
of malignant cancers (Fass, 2008). 
Second, by using tracer targets, NIR fluorescent molecular imaging yield high sensitivity 
and specificity with low autofluorescence background (Frangioni, 2003; Hilderbrand and 
Weissleder, 2010; Pysz et al., 2010). In the "NIR window" of 650-900 nm biological tissues 
have low light absorption, thus deep tissue penetration and sensitive detection could be 
achieved based on highly fluorescent molecular probes (Mahmood and Weissleder, 2003), by 
which tumors and small metastases could be specifically visualized. It can be used for in vivo 
diagnosis, as well as for therapeutic testing. In humans, it can also not only improve the 
diagnosis of cancer, but also assist radical resection of malignancy, which is essential for 
current cancer treatment.  
 
1.2.3 CEACAM5 is a potential target for NIR fluorescent molecular imaging 
1.2.3.1 Structure of the CEACAM family 
The carcinoembryonic antigen-associated cell adhesion molecule (CEACAM) gene family 
contains 33 genes, 22 of which are expressed (Hammarstrom, 1999). All family members have 
similar structural characteristics with variable and/or constant domains. This group is divided 
into two main groups: 1) CEACAM; 2) pregnancy-specific glycoprotein (PSG) subgroup. 




N-terminal IgV-like domain  IgC-like domain, A, B subset 
N-glycosylation site          GPI-anchor in lipid bilayer 
Fig.1-2: Schematic model of CEACAMs family members nomenclature (Beauchemin et al., 
1999; Hammarstrom, 1999) 
According to their anchoring membrane, they can be again divided into two groups: 
CEACAM5 (CEA), CEACAM6, CEACAM7, and CEACAM8 belong to 
glycophosphatidylinositol (GPI) anchor members, while CEACAM1, CEACAM3, and 
CEACAM4 are transmembrane members. 
These membrane-bound proteins could be secreted into circulation. Of which, CEACAM5 
has an important regulating influence on differentiation and proliferation of cancer cells. 
Overexpression of CEACAM5 may contribute to the development of many digestive or 
pulmonary cancers. 
1.2.3.2 Expression of CEACAM5  















































CEACAM5, as a well-known tumor marker with a molecular weight of 180,000, is first 
described in human colon cancer tissue extracts by Gold and Freedman (Gold and Freedman, 
1965). Its expression in the normal epithelium is very low, however, during carcinogenesis, 
CEACAM5 has a high expression in many epithelial originated malignancies (Hefta et al., 1998; 
Shively and Beatty, 1985). Adenocarcinoma of the pancreas is of no exception, where increased 
CEACAM5 expression has been reported (Albers et al., 1988; Allum et al., 1986; 
Hammarstrom, 1999; Yamaguchi et al., 1991). In addition, the protein can be secreted into the 
circulatory system and be measured as a serum tumor marker that reflects the disease burden. 
1.2.3.3 Protein epitopes of CEACAM5 
 
Fig.1-3 The GOLD epitope groups of CEACAM5. (Bjerner et al., 2002; Hammarstrom et 
al., 1989) 
Human CEACAM5 is the first tumor marker subjected to epitope mapping by International 
Society for Cancer Developmental Biology and Medicine (ISOBM) (Hammarstrom et al., 
1989). CEACAM5 consists of an N-terminal IgV-like domain (N) and six IgC-like domains 
( A1-3 and B1-3). It is anchored by a glycosylphosphatidylinositol to the top of epithelial cells 
(called C). Therefore CEACAM5 can be formulated as N-A1B1-A2B2-A3B3-C via domains 
(Bjerner et al., 2002; Hammarstrom et al., 1989).   
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According to the specificity of domain binding, five non-overlapping epitopes were divided 
(Fig.1-3) (Bjerner et al., 2002; Hammarstrom et al., 1989):  In A3B3 domain there are GOLD 
epitope group 1 and 3; in A2B2 domain it is group 2; in A1B1 domain it is group 4; and in N 
domain binding it is group 5. However, many monoclonal antibodies against CEACAM5 were 
reported to have immunological cross-reactivity with NCA (CEACAM1) due to the high 
sequence homology in the CEACAMs subfamily (von Kleist et al., 1972) and BGP 
(CEACAM6) (Hinoda et al., 1988). 
1.2.3.4 CEACAM5 is a promising target for molecular imaging of pancreatic cancer 
Pancreatic cancer has very poor survival because its symptoms and diagnosis typically 
occur at an advanced stage. As CEACAM5 is selectively expressed in pancreatic cancer cells, 
NIR fluorescent molecular imaging targeting CEACAM5 is beneficial for diagnosis.  
Some studies pointed out that circulating level of CEACAM5 in patients with pancreatic 
cancer increased, suggesting that serum CEACAM5 concentration can be used as a diagnostic 
tool and therapeutic monitoring marker. However, due to the high variability among individuals, 
circulating CEACAM5 concentration cannot yet yield sufficient sensitivity or specificity for 
diagnosis. In vivo imaging may provide a true expression of CEACAM5 thus more reliable 
than serum level. 
CEACAM5 may be a good target for NIR fluorescent molecular imaging in vivo. Some 
authors reported improved pancreatic cancer fluorescence imaging by modifying monoclonal 
antibodies targeting CEACAM5 epitope GOLD 1 and the results showed a higher tumor-to-
background ratio (Lwin et al., 2018).  
1.3 Fluorescence-Guided Surgery 
Based on intraoperative NIR fluorescence imaging technology, the recent fluorescence-
guided surgery (FGS) has become a surgical modality. FGS can help surgeons visualize the 
primary tumor, all metastatic lesions and their margins during surgery by combining tumor 
targeting antibodies with fluorophores. And it has been shown to prolong tumor-free survival 
in orthotopic animal models (Hiroshima et al., 2014; Metildi et al., 2014; Metildi et al., 2013; 
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Uehara et al., 2015; Yano et al., 2015a; Yano et al., 2015b; Yano et al., 2016; Yano et al., 
2015c). 
1.4 Aim of the study 
The identification of cancer cell specific and membranous antigens has laid the foundation 
for opening the door to molecular imaging known as a living "immunohistochemistry", which 
may be promising in many aspects of cancer diagnosis and treatment in the future. 
So far, various imaging targets for PDAC have been explored (Li et al., 2018b; Luo et al., 
2017; Neesse et al., 2013; Trajkovic-Arsic et al., 2014).  
Urokinase plasminogen activator receptor (uPAR) reveals over expression on the surface 
of pancreatic cancer cells. Yang et al. reported a promising NIR fluorescent molecular imaging 
for detection of pancreatic cancer by targeting uPAR with a novel nanoparticle probe (Yang et 
al., 2009). 
Dr. Willmann and his colleagues compared the histological and immunohistochemical 
analysis of VEGF receptor 2 targeted molecular images (mouse pancreas) with CD31 (vascular 
endothelial cell marker) and VEGF receptor 2. The results showed that the average diameter of 
1.7 mm pancreatic micro tumor could be detected by ultrasound molecular imaging (Willmann 
et al., 2008a; Willmann et al., 2008b; Willmann et al., 2008c; Willmann et al., 2008d) 
Apart from the uPAR and VEGF receptor, integrin αvβ3, claudin-4 and carbohydrate 
antigen 199 were also reported in application. (Li et al., 2018b; Luo et al., 2017; Neesse et al., 
2013; Trajkovic-Arsic et al., 2014). 
However, the above-mentioned pancreatic cancer cell antigens may not have stable 
expression, and there is no possibility of clinical transformation in the short term. Finding more 
specific and sensitive cell surface antigen of pancreatic cancer cells may be one of the 
breakthrough points in clinical transformation of near infrared fluorescence imaging of 
pancreatic cancer. 
CEACAM5 seems to be an attractive target for NIR fluorescent imaging in pancreatic 
malignancy as it is of high expression of CEACAM5. Through targeting CEACAM5 with 
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epitope 1, it was reported to represent a possible strategy to improve the ability of detecting 
pancreatic cancer and delineating the tumor margins in the operating field (Lwin et al., 2018).  
Our team had cloned a monoclonal antibody of C1P83 against CEACAM5 targeting its 
epitope GOLD 3 (Nap et al., 1992; Schmiegel et al., 1985). The study aims at exploring a 
modality of NIR fluorescent molecular imaging of pancreatic cancer targeting CEACAM5 on 
epitope GOLD 3, which may be expected to evolve into the application of future fluorescent 
surgical navigation.
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2. Materials and Methods 
2.1   Animals and cell sources 
Four-week-old female immunodeficient C57BL/6 FoxN1nu mice (Harlan) were obtained 
with weight from 20 g to 25 g provided by the animal center of UKSH. Animal experiments 
were carried out under institutional guidelines and certified by the Animal Experiment Ethics 
Committee of UKSH [number, V312-72241,121-33(8-1/12]. 
Two PDAC cell lines (PANC-1, BxPC-3) and MC38 (methycholanthrene-induced murine 
colon carcinoma cell line) were obtained from UKSH. The C15A3 cell line (a stable 
CEACAM5-expressing transfectoma from MC 38) was a gift from Dr. rer. nat. Stefanie Nittka 
from the University Hospital Mannheim. PANC-1 and BxPC-3 cells were cultured in RPMI 
1640 medium, while MC38 and C15A3 in DMEM medium with 1 mg/ml G418 contained in 
the culture medium for C15A3. 
2.2   Materials  
2.2.1  Main Instruments  
Description (Type) Company 
Beckman Coulter DU 800CW UV/Vis 
Spectrophotometer 
Beckman Coulter, Inc. 
High frequency ultrasonics (The Vevo® 770 
system) 
FUJIFILM VisualSonics 
Flow cytometry system (BD FACSCaliburTM) BD Biosciences, USA 
Heidolph duoMax-Rotator shake (1030) Heidolph Instruments GmbH, 
Schwabach 
Magnetic stirrers (MR300T) Heidolph  Instruments  GmbH, 
Schwabach 
Odyssey Infrared Imaging System (2.1) Li-COR Bioscience 
Vortex (Vortex Genie2) Scientific industries Inc., USA 
Water bath (WBT12) Reiss-Daimler Medingen 
VisEn FMT 2500TM LX VisEn™ Medical, Bedford, MA 
 
2.2.2  Kits 
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Description                            Company   
IRDye® 800CW kit LI-COR Biosciences, Lincoln, NE, USA  
FluoroTag™ FITC Conjugation Kit          Sigma-aldrich USA 
ZebaTM Desalt Spin Columns               Thermo Scientific 
Purified Mouse IgG (whole molecule);       GenScript, NJ, USA  
Slide-A-Lyzer™ Dialysis Cassettes   
(0.5-3ml/3-12ml/12-30ml) 
Thermo scientific   
 
2.2.3  Software 
Description                            Company   
TrueQuant imaging software PerkinElmer 
The Vevo® 2100 system software  FUJIFILM VisualSonics 
ABI Prism 7700 SDS software Applied Biosystems) 
Windows XP SP2 Microsoft Inc. 
SDS 2.1 software Applied Biosystems 
SPSS windows 22.0 SPSS Inc. 
GraphPad Prism 6  GraphPad Software Inc.  
 
2.3 Methods 
2.3.1 Production and purification of the anti-CEACAM5 monoclonal antibody: C1P83 
C1P83 was provided by Prof. H. Kalthoff (Christian Albrechts University; Kiel, Germany). 
The production technique was described previously(Nap et al., 1992; Schmiegel et al., 1985). 
The specificity and affinity of C1P83 against CEACAM5 (epitope GOLD 3) have been 
validated(Nap et al., 1992). 
2.3.2 Conjugation of C1P83 and mouse IgG (control) with IRDye800CW. 
The protocol followed is according the manufactureres instructions using the protein labelling 
kit for IRD800CW. The main steps are listed below.  
2.3.2.1 Preparation of Protein Solution for Conjugation 
100 µg of protein at a concentration of 1 (± 0.1) mg / mL was prepared in phosphate buffer 
(pH 8.5). Before reacting with IRDdye 800CW, cool / heat the protein to 20-25ºC. 
2.3.2.2 Protein Labeling Reaction 
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Mix the appropriate amount of IRDdye800CW with 100 µg protein according to the Figure 








Fig.2-1 IRDdye800CW volume and the molecular weight of the protein 
2.3.2.3 Conjugates of C1P83-IRDye 800CW and IgG-IRDye 800CW were purified by 
dialysis. 
Conjugates of C1P83-IRDye 800CW and IgG-IRDye 800CW were purified by the Zebra 
Desalting Spin Columns and the kit of Slide-A-Lyzer™ Dialysis Cassettes (0.5-3ml/3-12ml/12-
30ml). 
2.3.2.4 Calculation of Dye/Protein Ratio and Protein Concentration 
Measure the absorbance of the conjugate at 280 nm and 689 nm (A280 and A780). Then 
calculate the dye/protein ratio using the following formula: 
                    
Calculate the final protein concentration using the following formula:    
            
εDye is 270,000 M-1 cm-1 and εProtein is 203,000 M-1 cm-1 (for a typical IgG) in a 1: 1 
mixture of PBS: methanol.  
2.3.3 FACS analysis for CEACAM5 
2.3.3.1 FITC labelling of antibody of C1P83 and IgG 
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The protocol followed is according the manufacturers instructions using the Fluortag FITC 
conjugation kit. The main steps are listed below.  
 
Antibody preparation: Prepare 1 ml antibody solution with 5.0 mg / ml in 0.1 M bicarbonate 
buffer (pH 9.0). Add 0.2 ml (1.0 mg) of the antibody solution to each reaction vessel labeled 
"5: 1", "10: 1", or "20: 1". 
FITC preparation: Redissolve a bottle of FITC (F7250) in 2 ml of 0.1 M carbonate 
bicarbonate buffer, and spin until all FITC is dissolved. Label the vial with "20: 1 FITC". The 
"20: 1 FITC" solution is also used to make "5: 1" and "10: 1" solutions.  
Labelling: Add 50 ml of the appropriate FITC dilution to the corresponding labeled reaction 
vessel with stirring without light. 
Dialysis: Labeled proteins were isolated by dialysis. 
Calculating: Based on the absorbance values of the conjugate samples (A280 and A495), 
the protein concentration and F/P of the fluorescein-antibody conjugate is calculated according 
to the following formula:  
         
         
2.3.3.2 FACS for CEACAM5 quantification analysis in different cell lines 
1) Sample preparation: The cells were centrifuged at 500 × g for 5 minutes and washed 
three times in an isotonic PBS buffer. Adherent cell lines Pretreatment with 0.5 mM EDTA 
may be required to facilitate removal from their substrates. 
2) Harvest cells and Fc block cells with blocking IgG (1 µg IgG / 106 cells) for 15 minutes 
at room temperature. 
3) Add conjugated antibody (10 µl / 106 cells or a previously titrated amount). 
4) Remove all unbound antibodies by washing and centrifuge the suspended cells at 300 g 
for 5 minutes and decant the buffer. Resuspend the cells by adding 2 ml flow cytometry staining 
buffer. Repeat the washing process twice. 
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5) Resuspend the cells in 200-400 µl staining buffer for the final flow cytometric analysis. 
2.3.4 Immunostaining for CEACAM5 location in BxPC-3 cell line 
The monoclonal antibody C1P83 was used which recognizes the epitope GOLD 3 of 
CEACAM5. And IgG was also used as a control. In the control group, 1st Ab: ms IgG, 2nd Ab: 
anti-ms IgG-HRP; in C1P83 group, 1st Ab: C1P83, 2nd Ab: anti-ms IgG-HRP. Visualization 
was carried out with a peroxidase – diaminobenzidine kit (Dako)  
2.3.5 In vitro binding experiments 
For affinity measurements, 100,000 BxPC-3 cells / well were seeded into 6-well plates and 
allowed to adhere overnight. The next day, the medium was aspirated, the cells were blocked 
with 4% skim milk powder in PBS, and the cells were incubated with 2 ug of IRDye800CW-
labeled C1P83 in 2% skim milk powder in PBS at 4 ° C for 2 h or 24 h. dark. Cells were washed 
3 times with PBS, and fluorescence was measured and quantified using a Li-COR Odyssey 
infrared imaging system (λEx = 785 nm; λEm = 800 nm). 
2.3.6. In vivo experiments 
2.3.6.1. Animal tumor model 
2.3.6.1.1. Subcutaneous tumor model 
The subcutaneous tumor model has CEACAM5-positive tumors (C15A3, 1 × 106 cells) in 
the left abdomen and CEACAM5-negative tumors (MC38, 1 × 106 cells) in the right abdomen 
in the Four-week-old immunodeficient C57BL/6 FoxN1nu mice (Harlan), so each mouse can be 
used as its own control. They were allowed to grow for 10 to 14 days, and imaging was started 
when significant tumors appeared. 
2.3.6.1.2. Orthotopic tumor model 
The aesthesis was performed by 80 mg / kg ketamine (Aveco Co., Inc.) and 10 mg / kg 
xylazine (Rugby Laboratories, Inc.). A small (1 cm) lateral subcostal laparotomy was 
performed. One million CEACAM5 positive BxPC3 cells were orthotopically injected under 
the capsule of the pancreas in the Four-week-old immunodeficient C57BL/6 FoxN1nu mice 
(Harlan). The tumor growth was monitored by ultrasound and the tumors were able to grow 28 
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days before imaging. NIR fluorescence was visualized at various times with an FMT2500 
imager (λEx = 779 nm; λEm = 795 nm). Mouse IgG-IRDye800CW conjugates were injected 
as controls. 
2.3.6.2. In vivo high-resolution sonography  
Tumor volume was assessed by Vevo 770 small animal micro-imaging system 
(VisualSonics, Toronto, Ontario, Canada) using the Visual Sonics image analysis software 
package to define a three-dimensional region of interest. Select the tumor area of interest by 
acquiring ultrasound images that displays the maximum lateral diameter of the tumor for 
analysis.  
2.3.6.3. In vivo high-resolution MRI 
MRI imaging was performed on xenografted mice under general anesthesia with 
isoflurane by a 7-T MRI for small animal imaging (Cliniscan, Bruker Biospin GmbH, Ettlingen, 
Germany) with protocols as described in the literature (Will et al., 2016). 
2.3.6.4. NIR fluorescent molecular imaging in vivo and Image ex vivo 
Images were taken daily by FMT2500LX until 7 days after the injection. The same size of 
the region of interest (ROI) was used for the comparison between the two groups. In addition, 
an ROI of the same size was generated in a representative region without tumor tissue in order 
to determine the background fluorescence. 
2.3.7. Histological Study 
Histological study was composed of Hematoxylin and Eosin Staining, Masson's 
Trichrome Staining and Microvessel density detection for tumor tissues. 
Masson's Trichrome Staining was used to detect collagen fibers in tissues on formalin-
fixed sections embedded in paraffin. The collagen fibers are colored blue and the cores are 
colored black and the background is colored red.  
Microvessel density (MVD) was assessed by immunohistochemical staining with anti-
CD31 antibodies. MVD was determined by identifying the three most intense neovascular 
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regions of each sample and counting at low magnifications (100x magnification). Record 
average number of vessels in three selected areas 
2.3.8 Statistical analysis  
Statistical analysis was carried out by IBM SPSS Statistics version 23.0 and 
GraphPad Prism7.0. Mann-Whitney U test or one-way ANOVA was used with one variable 
involved. When there were two variables, two-way ANOVA was used for analysis. P values < 
0.05 was were considered to be statistically significant. Spearman rank correlation coefficient 




3.1 CEACAM5 qualitative and quantitative analysis in different cell lines 
3.1.1 Human BxPC-3 pancreatic cancer cell line is CEACAM5 positive by FACS analysis 
and immunocytochemistry 
To determine the expression of CEA on pancreatic tumor cell lines for the purposes of 
establishing an orthotopic in-vivo tumor model for testing the antibody, the C1P83 antibody 
was incubated with BxPC3 and Panc1 cell lines and detected using a secondary antibody 
conjugate to FITC and analyzed by flow cytometry.  
 
FACS analysis 
FACS analysis indicated that BxPC-3 is a CEACAM5-positive cell line (Fig.3-1B) (Fig.3-
1A) 
 
Fig.3-1 FACS analysis showed that human BxPC-3 pancreatic cancer cell line is 
CEACAM5 positive. 
 
Further immunocytochemistry showed that CEACAM5 is expressed on the membrane of 




Fig.3-2 Immunocytochemistry showed CEACAM5 is expressed on the membrane of 
BxPC-3 pancreatic cancer cells (B). A(control): 1st Ab: ms IgG, 2nd Ab: anti-ms, IgG-HRP. B: 
1st Ab: C1P83, 2nd Ab: anti-ms IgG-HRP. 
3.1.2. Human PANC-1 pancreatic cancer cell line is CEACAM5 negative 
FACS analysis showed the PANC-1 cell line is a CEACAM5 negative cell line. 
 
Fig.3-3. FACS analysis showed that PANC-1 pancreatic cancer cell line is CEACAM5-
negative.  
3.1.3. Murine CEACAM5+ C15A3 cell line is CEACAM5 positive  
To establish a positive control for determining CEA expression in-vitro and in-vivo, the 
CEACAM5+ C15A3 murine colon carcinoma cell line (stably transfected with human 
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CEACAM5) was utilized. Cells were incubated with the primary antibody and primary 
antibody binding was detected by a secondary antibody conjugated to FITC. C15A3 cell line 
was confirmed to be CEACAM5 positive by FACS analysis. (Fig.3-4A, Fig.3-4B ) 
 
Fig.3-4 FACS analysis showed that C15A3 cell line (stably transfected with human 
CEACAM5) is CEACAM5 positive.  
3.1.4. Murine CEACAM5- MC38 cell line is CEACAM5 negative  
FACS analysis showed that that MC38 murine colon carcinoma cell line is CEACAM5-




Fig.3-5 Negative expression of CEACAM5 in MC38 cell line by FACS.  
 
3.2 CEACAM5 targeted NIR fluorescent imaging: in vitro experiment 
3.2.1 C1P83-IRDye800CW specifically bind to CEACAM5 positive BxPC-3 cells 
For in-vivo detection of antibody binding, it is advantageous to use near-infrared 
fluorochromes since the emission wavelength is minimally absorbed by bodily fluids and tissue. 
However, conjugation of the fluorochrome to the antibody may alter binding of the antibody to 
its target. The antibody C1P83 was conjugated to IRDye800CW on lysine residues. To ensure 
that the conjugated antibody maintained binding activity to the target epitope, in-vitro binding 
experiments were performed. Li-COR Odyssey infrared imager indicated that the conjugates 
of C1P83-IRDye800CW could specifically bind CEACAM5 positive BxPC-3 pancreatic 
cancer cells; CEACAM5 positive BxPC-3 pancreatic cancer cells had significantly higher 
fluorescence (pmol) than CEACAM5-negative PANC-1 pancreatic cancer cells (P <0.05). 
(Fig.3-6) (After the conjugation with IRD800CW for C1P83, the Dye/Protein Ratio was 2, and 






Fig.3-6 CEACAM5 targeted NIR fluorescent molecular imaging in vitro in BxPC-3 and 
PANC-1 cancer cells. A: C1P83-IRDye800CW was added to BxPC-3 cell culture medium for 
2 hours (six-well plate); B: C1P83-IRDye800CW was added to PANC-1 cell culture medium 
for 2 hours (six-well plate); C: Comparison of fluorescence (pmol) 2 hours after the addition of 
C1P83-IRDye800CW in vitro between BxPC-3 and PANC-1 cell lines in six-well plate (P 
<0.01).  
3.3 CEACAM5 targeted NIR fluorescence molecular imaging in vivo: subcutaneous 
tumor model  
To establish specificity in detection of CEA expressing tumors in-vivo using the C1P83-
IRD800CW, an in-vivo experiment was performed in mice harboring CEA non-expressing and 
CEA expressing tumors. The CEA negative cell line MC38 was inoculated subcutaneously on 
one flank of the mice and the CEA expressing cell line C1P83 on the opposite flank. Of note 
was the rapid growth of MC38 in contrast to C15A3 tumors which remained small. Despite the 





Fig.3-7 CEACAM5 targeted NIR fluorescent molecular imaging of subcutaneous tumor. 
MC38 (left): CEACAM5-, C15A3 (right): CEACAM5 + 
As shown in Fig.3-7, after injection of 25ug IRDye800CW labelled antibody into the mice 
by the tail vein (n = 5), the NIR fluorescence imaging model of subcutaneous tumors showed 
that the fluorescence intensity (nM) of CEACAM5 positive C15A3 subcutaneous tumors were 
significantly higher than that of CEACAM5 negative MC38 subcutaneous tumors, and the 
fluorescence intensity peaked around 48 hours after C1P83-IRDye80CW injection (Fig. 3-8). 
 
 




3.4 CEACAM5 targeted NIR fluorescent molecular imaging in vivo: orthotopic 
pancreatic tumor model 
To test the sensitivity of the antibody in a more clinically relevant mouse model, mice were 
orthotopically inoculated with the BxPC3 cell line. Two weeks after orthotopic inoculation, 
tumors can be detected by 3-D ultrasound in each mouse, with the diameter 3-5 mm. The NIR 
fluorescent imaging was performed about four weeks after orthotopic inoculation. For 
orthotopic tumor imaging, after the conjugation with IRD800CW for C1P83, the Dye/Protein 
Ratio was 2, and the concentration was 0.5 ug/ul; mouse IgG Dye/Protein Ratio was 1.1, and 
the concentration was 1.2 ug/ul. 
3.4.1. Dosage with 25 ug C1P83 or IgG injected. 
(1) IgG control group: 
As shown in Fig.3-9: After the injection of 25ug IRD800CW labelled IgG, most of the NIR 
fluorescence (nM) stayed in the liver, and the tumor-specific fluorescence (nM) at the tumor 
site was very weak. (n = 3) 
 
Fig.3-9 NIR fluorescent imaging of pancreatic orthotopic tumor (25 ug IgG, control group) 
(2) C1P83 group: 
As shown in Fig.3-10, the tumor-specific NIR fluorescence signal was significantly 
increased compared with the control group, and the fluorescence intensity peaked after 48-72 




Fig.3-10 NIR fluorescence imaging of pancreatic orthotopic tumor (25 ug C1P83 group) 
(3) Time and fluorescence 
The results suggested that the NIR fluorescence in the C1P83 group was higher than that 









Fig.3-11 Time-fluorescence curve. (bg: background) (n=x Control IgG bg, n=y Control 
IgG tumor, n=z C1P83 tumor, n=xx C1p83 Ab bg) 
 
(4) Tumor-to-background ratio: 
The results suggested that the NIR fluorescent tumor-to-background ratio (TBR) of the 
C1P83 group is significantly higher compared with that of the IgG group (P < 0.05), and the 
TBR does not increase significantly with time (Fig. 3-12) (P = 0.295). 
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Fig.3-12 NIR fluorescent tumor-to-background ratio (25ug dosage group) 
(5) Ex vivo imaging, biodistribution and histological study 
Ex vivo NIR fluorescent imaging (144 hours after injection of IRD800CW labelled 
antibody) showed that the NIR fluorescent (nM) of the tumor tissue was significantly higher 
than that of liver, spleen, and kidney (see Fig.3-13, Fig.3-14). Tumor weight-fluorescence curve 
showed that there was a correlation between the tumor weight (ex vivo) and the fluorescence 
(pmol) (R2 = 0.8017, P <0.0001) (Fig.3-15).  
 
Fig.3-13 Biodistribution of NIR fluorescence ex vivo. IgG control group: (A): In vivo NIR 
fluorescent molecular imaging of tumors in the IgG control group; 
(B): Ex vivo NIR fluorescent molecular imaging of tumors in the IgG group; 
(C): Ex vivo NIR fluorescent molecular imaging of liver, spleen, and kidney in the IgG 
group; 
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(D): In vivo NIR fluorescent molecular imaging of tumors in the C1P83 group; 
(E): Ex vivo NIR fluorescent molecular imaging of tumors in the C1P83 group; 








































Fig.3-15 Tumor weight was correlated with the fluorescence (R2 = 0.8017, P <0.0001, 
Equation: Y = 30.40 * X-5.656) (25 ug group)  
As shown in Fig.3-16, the tumors were confirmed ex vivo by H-E staining. 
 
Fig.3-16 H-E staining of pancreatic cancer tumor. 
 
3.4.2. dosage with 100 ug C1P83 or IgG injected: 
To determine if sensitivity of tumor detection could be increased with higher doses of the 
antibody, the TBR was determined using 100ug of antibody in mice harboring BxPC3 tumors. 
 
(1) 100 ug IgG control group 
As shown in Fig.3-17: Most of the NIR fluorescence in the 100 ug IgG control group 
retained in the liver, and the tumor-specific fluorescence at the tumor site was very weak but 




Fig.3-17 NIR fluorescent imaging of orthotopic pancreatic tumors (100 ug IgG control group) 
 
(2) 100 ug C1P83 group 
As shown in Fig.3-18, the tumor-specific NIR fluorescence was significantly increased in 
100 ug C1P83 group, and the tumor fluorescence peaked after 48-72 hours; and the fluorescence 
can be maintained for nearly one week. (n = 5) 
 
Fig.3-18 NIR fluorescence imaging model of pancreatic orthotopic tumor (100 ug C1P83 
group). 
(3) Time and fluorescence 
The results suggested that the NIR fluorescence (nM) of the tumor in the 100ug C1P83 
group was significantly higher compared with that in the 25ug C1P83 group (P < 0.05). The 














Fig.3-19 Time-fluorescence curve. 
(4) Tumor-to-background ratio: 
The results suggested that the TBR of the 100ug C1P83 group was higher than that of the 
25ug C1P83 group, but the difference between the two groups did not reach a statistically 
significant level (P = 0.07). (Fig.3-20) 
 
Fig.3-20 NIR fluorescent tumor-to-background ratio (TBR).  
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(5) Overall correlation between FMT and MRI 
MRI of orthotopic pancreatic tumors (n = 9): 
After the pancreatic orthotopic tumor model had been successfully established, 7-T MRI 
was performed for imaging of the tumors in mice, and the tumor volume was calculated with 
the respective software of each modality. As shown in Fig.3-21, 7-T MRI could perform sagittal, 
coronal, and cross-sectional imaging of pancreatic orthotopic tumors. 
Fig.3-21 Magnetic resonance imaging of pancreatic orthotopic tumors 
 
Relationship between pancreatic tumor volume and NIR fluorescence (n = 9): 
Each mouse was injected with 100 ug of C1P83-IRDye800 conjugate in the tail vein. After 
72 hours, NIR fluorescent molecular imaging was performed with a FMT2500 imager, and then 
7-T MRI was used to perform magnetic resonance examination and calculation of tumors 
volume (mm3). As shown in Fig.3-22 and Fig.3-23, the NIR fluorescence (pmol) of the 
pancreatic orthotopic tumor and the magnetic resonance tumor volume (mm3) showed a good 






Fig.3-22 Correlation between NIR fluorescence of pancreatic orthotopic tumors and 
magnetic resonance tumor volume (Pearson r = 0.9188, 95% confidence interval: 0.6531-
0.9831, R2 = 0.8441, P = 0.0005, X-Y pairs = 9) 
 
Fig.3-23 NIR fluorescent molecular imaging and magnetic resonance imaging of pancreatic 
orthotopic tumors (A: FMT2500 NIR fluorescent molecular imaging of pancreatic tumor in 
vivo; B: 7T MRI of pancreatic orthotopic tumor) 
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(6) Ex vivo imaging, biodistribution and histological study 
Ex vivo NIR fluorescent imaging and biological distribution of fluorescence (nM): 
The ex vivo NIR fluorescent imaging showed that the fluorescence (nM) of the tumor in 
the 100 ug C1P83 group was significantly higher than that of the liver, spleen, and kidney (see 
Fig. 3-24, Fig. 3-25). 
  
Fig.3-24 NIR fluorescent imaging of pancreatic orthotopic tumors and biological 




Fig.3-25 Ex vivo NIR imaging and biological distribution of fluorescence. 
Tumor weight and fluorescence: 
As shown in Fig.3-26, the tumor weight (g) was correlated with the NIR fluorescence (pmol) 








Fig.3-26 Correlation between pancreatic orthotopic tumor weight and NIR fluorescence 
(100 ug C1P83 group) (R2 = 0.7722, P = 0.0041, Equation: Y = 107.6 * X + 14.46)  
Biological distribution ex vivo NIR fluorescence and time: 
The samples at 6/24/48 hours were 3 cases each. After injection of 100 ug IRD800CW 
labelled C1P83, ex vivo NIR fluorescent imaging was performed at 6/24/48 hours to detect 
fluorescence for each organ. The results suggested that the liver was the main site for non-
specific accumulation of fluorescence (P < 0.05), but the signal was considerably decreased 



















after 24 hours (P < 0.05) (Fig. 3-27). (6hrs sample n = 3, 24hrs sample n = 3, 48hrs sample n = 
3) 
 
Fig.3-27 Biological distribution of ex vivo NIR fluorescence (6/24/48 hours) 
Histological study: 
In the therapeutic setting, the limited localization and penetration of monoclonal antibodies 
into solid tumors restricts their antitumor efficacy. Pancreatic adenocarcinoma cells grow in 
fibrotic stroma abundant in extracellular matrix components, mostly collagen, and the stroma 
is poorly perfused. To characterize perfusion and fibrosis of the BxPC3 tumor, staining for 
blood vessels and fibrosis was performed. 
Evaluation of microvessel density (MVD, CD31) and fibrous collagen status of the 
orthotopic tumors showed that the MVD and fibrous interstitial substance of xenografted 
tumors were abundant. It indicated that this experimental tumor tissues had good vascular 
permeability and the potential for therapeutic delivery of drugs by the antibody. (Fig. 3-28; Fig. 
3-29; Fig. 3-30) 
 
Fig.3-28 Masson's trichrome stain method to evaluate the state of neoplastic fibrous 








Fig.3-30 Evaluation of MVD after NIR fluorescence imaging of pancreatic orthotopic tumors  
 
(7) Detection of small tumors or metastasis: NIR fluorescent molecular imaging  
To test the sensitivity of the antibody in detecting micro-metastasis, the bulk of the tumor 
was resected under white light but a visible small pocket of tumor was left unresected. 
Following resection, the mice injected with the labelled antibody were imaged later to 
determine if the small unresected residual tumor could be detected. Upon detection, the residual 





Fig.3-31 NIR fluorescent imaging could find micrometastasis of the tumor (1)  
A: tumor in vivo status; B: tumor removal status; C: pathological confirmation; D: tumor 
in vivo status in FMT2500; E: micrometastasis in vivo in FMT2500; F: micrometastasis 
removal status in FMT2500; G: tumor in vivo status by NIR fluorescence imaging in FMT2500; 
H: micrometastasis in vivo status by NIR fluorescence imaging in FMT2500 (pathologically 
confirmed); I: NIR fluorescent imaging after micrometastasis removed; (Arrows indicate) 
 
Arrows indicate  
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4. Discussion  
In the study, we demonstrated the feasibility of CEACAM5 targeted NIR fluorescent 
molecular imaging in a xenografted immunodeficiency mouse model of pancreatic cancer by a 
novel monoclonal antibody C1P83 labeled with IRDye800CW. The monoclonal antibody 
C1P83 targets CEACAM5 at epitope GOLD 3 (Hammarstrom et al., 1989). By a controlled 
antibody of IgG, the specificity and sensitivity of detection was tested and the in vivo 
distribution of nonspecific signal was verified. Additionally, the xenografted tumor model 
showed that C1P83-IRDye800CW was able to find tiny tumors or micro-metastasis, which 
indicated its potential specific diagnostic value and surgical navigation application in the near 
future.  
 KRAS TP53 P16/CDKN2A SMAD4 
BxPC3 WT Mutation Mutation(product 
absent) 
Mutation 
PANC-1 Mutation Mutation Deletion (product 
absent) 
WT 
Table 4-1 Genotype of pancreatic cell line between BxPC3 and Panc1. 
In the present study, the chosen pancreatic cancer cell lines were BxPC3 and Panc1. 
Originally, BxPC-3 cell line was cultured from an old female pancreatic adenocarcinoma of the 
body and expressed carcinoembryonic antigen with a moderate differentiation in phenotype. 
While PANC-1 cell line was cultured from an invading pancreatic adenocarcinoma of the head 
and did not express carcinoembryonic antigen with a poor differentiation in phenotype. 
Genotype of these two cell lines are listed in Table 4-1 and the relationship of genotye and 
phenotype remains unclear as the studies to assess the relation of such mutations and cell 
behavior are too few(Deer et al., 2010). KRAS mutations seem to be the most common mutation 
in pancreatic cancer, and most available pancreatic cancer cell lines have KRAS mutations 
except BxPC-3 cell line. For examples, both CAPAN-1 and PANC-1 cell lines have KRAS 
mutations, but CAPAN-1 cells express CEACAM5 while PANC-1 cells do not express 
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CEACAM-5. The negative expression of carcinoembryonic antigen in PANC-1 may be 
correlated with multiple epigenetic alterations and the detail mechanism of this heterogenicity 
remains unclear. (Deer et al., 2010) 
Human CEACAM-5 was regarded as a poor prognostic factor in human digestive cancers; 
and some reported that CEACAM-5 positive BxPC-3 cells have higher tumorigenicity in tumor 
size than that of CEACAM-5 negative PANC-1 cells (Aubert et al., 2003; Miknyoczki et al., 
1999), while some reported the opposite results (Fukasawa and Korc, 2004) which indicated 
that the correlation between CEACAM-5 expression and pancreatic tumor growth remains 
inconclusive. In our subcutaneous model we found an interesting fact that the size of MC38 
(CEACAM-5 negative) subcutaneous tumor was much greater than that of C15A3 (CEACAM-
5 positive, transfected with human CEACAM-5), however the exact mechanism was unclear 
and needs to be further investigated. 
CEACMA5 was not only the target for fluorescence imaging, but also may serve as a 
therapeutic target. Reyes et al reported that multi-drug resistant cancer cells will be sensitive to 
the T cell bispecific antibody cibisatamab (CEA-TCB) which binds CEACAM5 on cancer cells 
and CD3 on T cells by pharmaceutically increasing CEA expression with WNT inhibitors 
(Gonzalez-Exposito et al., 2019). Interestingly, some other pharmacological agents such as 5-
fluorouracil, interleukins or interferons may also cause the up-regulation of CEACAM5 
expression (Aquino et al., 2004). This may have potential clinical interest relevant to cancer 
diagnosis and therapy for monoclonal antibody or tumor vaccines targeting CEACAM5 (Klein 
et al., 2017). 
In the present study, we found that the higher concentration resulted in higher tumor-to-
background ratio. Though the difference was not significant, our explanation is that it might 
due to limited samples. As C1P83 is an intact antibody which cannot be removed rapidly in 
vivo, too high concentration of antibody may also result in unacceptable background. 
Optimization seems necessary before translating into human application in the future. Another 
interesting phenomenon is that we found that the fluorescent signal could last for nearly one 
week, which might provide a promising target for immunotherapy.  
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Concerning the ratio of dye to protein for fluorescent imaging, some reported that 5:1 molar 
ratio of dye to protein was optimal for NIR fluorescent conjugation(Meincke et al., 2011). Some 
reported that the fluorescence intensity increased in parallel with higher dye to protein ratio as 
for the dye of IRDye800CW(Aldrich et al., 2011). In our preliminary study, stronger 
fluorescent signal could be achieved for higher dye to protein ratio within the range of 1-5:1. 
Over-labeling with higher dye to protein than 5:1 may result in high background, thus the 
sensitivity and specificity may be decreased. In prevention of distorted absorption spectrum, 
the final dye to protein ratio was about 2:1 for purified conjugates for in vivo imaging. 
It was believed that fibrous nature of pancreatic tumor interfered with antibody targeting 
diagnosis and therapy, while our tumor model of BxPC cell in mice indicated good vascular 
permeability, which is comparable with the literature; and both BxPC-3 and Capan-1 cell lines 
showed high angiogenic potential, while AsPC-1 and MIA PaCa-2 cell lines had low levels of 
angiogenic potential (Deer et al., 2010). However, this experimental tumor is different with the 
humanized tumor regarding the fibrosis, angiogenic potential and microenvironment, a patient-
derived xenograft (PDX) model is required to test the novel antibody of C1P83. 
Compared with previous fluorescent imaging studies targeting epitope 1 of CEACAM5 by 
humanized M5A mAb developed from T84.66, the time of peak fluorescent intensity and the 
TBR are similar with the present study (Lwin et al., 2018). Another study reported similar TBR 
of about 5 at 72 hours postinjection with single-chain anti-body fragment (Boonstra et al., 2015). 
And Studies of fluorescent imaging by C1P83 have not been reported by other authors. It 
indicated that further studies with multiple cell lines and mouse model should be performed 
and evaluated. 
Although the current results of this study are encouraging, our technology model is limited 
by the large molecular weight of intact antibodies and the only partial humanization of imaging 
models. Firstly, intact antibodies stay in the circulation longer (1-3 weeks), which gives them 
sufficient time to accumulate in the tumor. However, this means that it also takes several days 
for the fluorescent background of blood and normal organs to be removed, which makes them 
unsuitable as radiolabeled probes. The cycle time of a complete monoclonal antibody is 
Disccussion 
 41 
relatively long, and many research teams have evaluated it in clinical immunoPET studies over 
the years (Wu and Olafsen, 2008). Due to its long residence time in the blood, high non-specific 
background signals may hinder the diagnostic potential of intact antibodies (Sharkey et al., 
2010; Wu and Olafsen, 2008). Therefore, combining the recombinant antibody fragments 
(F(ab′)2, Fab, ScFv, and sdAb) with fluorescent probes directly for NIR fluorescent molecular 
imaging may greatly improve the imaging efficiency and back-to-ground ratio. The low 
immunogenicity of antibody fragments will also improve the safety of imaging. Secondly, the 
preclinical animal models have their limitations. Most current studies are performed on 
immunodeficiency animals. For human CEACAM5 targeted imaging, immunodeficient mice 
models are probably not adequate because rodents lack the gene of human CEACAM5. 
Consequently, the binding of the antibody to normal epithelium is unknown and the specific 
tumor signal is artificially augmented. (Chevinsky, 1991). Thirdly, the xenograft model using 
cancer cell lines is not sufficient to represent the complex heterogeneity of human tumor, and 
it could not reflect the patient’s response sufficiently. Moreover, the xenograft tumor often 
cannot recapitulate the tumor microenvironment and how the microenvironment will influence 
the fluorescent molecular imaging remains unknown. To overcome these limitations, a PDX 
model seems necessary as a more advanced preclinical cancer model. Fourthly, the model of 
micro-metastases detection was not performed in various pancreatic cancer cell lines and has 
not been verified in PDX tumor model. Moreover, the detection was performed after 
laparotomy with the main tumor removed, and the micro-metastases were not in the liver. For 
liver metastases, its signal may be masked by the liver signal due to the hydrophobicity of the 
IDye800CW, despite that the masking fluorescence would decrease rapidly to baseline within 
12-48 hours. Thus, it’s diagnostic potential in vivo for hepatic micro-metastases need to be 
further evaluated in liver metastasis models by comparison of MRI and fluorescent imaging. 
And for outlook, we envisage the following three directions mainly. 
First, The next generation of animal models. the In order to establish a more humanized 
animal model, CEABAC2 transgenic mice have been obtained, originally developed by Dr 
Clifford Stanners, from the Morris Goodman Cancer Center(Chan et al., 2006), The transgene 
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consists of a genomic insertion of two copies of intact 187 kb artificial human bacterial 
chromosomes (BAC) that contain most of the proximal human CEACAMs gene cluster. The 
CEABAC2 mice are genetically of the fvb strain and immunocompetent, so only tumor cell 
lines originated from the fvb strain could be inoculated into the CEABAC2 mice. We will use 
this "humanized" animal model to compare the binding of smaller FAB fragment of the 
antibody C1P83. 
Second, Development of next-generation antibodies. Develop antibody fragments of 
CEACAM5 monoclonal antibody C1P83 through genetic engineering, and combine antibody 
fragments (F(ab′)2, Fab, ScFv, and sdAb) directly with fluorescent probes for in vivo NIR 
fluorescent molecular imaging may greatly improve imaging efficiency and tumor-to-
background ratio. Reducing the immunogenicity of antibody fragments will also improve the 
safety of imaging. The monoclonal antibody recombinant fragment targeting CEACAM5 
antigen epitope GOLD 3 may have further application prospects. If I123 can be coupled to C1P83 
recombinant antibody fragments, it is expected to develop targeted SPECT diagnosis and 
treatment methods; if I131 or drug-containing liposomes or nanomaterials can be coupled to 
C1P83 recombinant antibody fragments, it is also expected to develop A new model of targeted 
therapy for pancreatic cancer. 
Third, The next generation of NIR-II fluorescent molecular imaging probes. Compared 
with the NIR-I spectrum of 700-900 nm, the tumor-to-background ratio and fluorescent 
imaging quality in the NIR-II spectrum of 1000-1700 nm are significantly improved (Diao et 
al., 2015). The advantages of NIR-II nanoprobes are obvious: due to the long emission 
wavelength, low scattering, photon absorption is almost negligible, and autofluorescence is also 
reduced to the lowest range (Hong et al., 2015). Therefore, the tissue penetration of NIR-II 
nanoprobe is better, and it has higher spatiotemporal resolution and deeper imaging depth in 
biological tissue imaging (Ding et al., 2018). Currently, popular NIR-II nanoprobes are single-
walled carbon nanotubes, rare-earth ion-doped nanocrystals, semiconductor quantum dots, 
small organic molecular materials, and conjugated polymers. 
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Small organic molecules can be designed and adjusted with fine spectroscopic properties, 
have high biocompatibility, fast excretion ability, simple and fast preparation methods, and 
have important advantages in molecular design based on the NIR-II region. Considering the 
application of NIR-II region imaging agents in clinical applications, probes based on small 
organic molecules are still the best candidate. Therefore, the development of NIR-II region 
probes based on small organic molecules is currently a hot area of research. (Antaris et al., 2016; 
Antaris et al., 2017; Cosco et al., 2017; Feng et al., 2017; Li et al., 2018a; Shou et al., 2017; 
Sun et al., 2017; Sun et al., 2016; Sun et al., 2018; Zhu et al., 2017). 
To date, only two NIRF probes, IRDye800CW and ICG, have passed safety tests and are 
allowed to be used clinically (Whitley et al., 2016). If the NIR-II spectrum fluorescent probe 
can be bound to C1P83 or its recombinant antibody fragment, combined with multimodal tumor 





CEACAM5 is a potential molecular target for visualization and localization of CEACAM5 
expressing cancers by NIR (NIR) fluorescence imaging. We synthesized conjugates of 
CEACAM5 monoclonal antibody C1P83 (targeting epitope Gold 3 of human CEACAM5) with 
NIR fluorescent dye of IRDye800CW. Purified conjugates of C1P83-IRDye800CW were tested 
for binding selectivity in vitro of human BxPC-3 cancer cells that express CEACAM5, and the 
Binding was time-dependent. Conjugates failed to label the PANC-1 cells which is a 
CEACAM5 negative control. In the subcutaneous tumor model in immunodeficient mice, 
subcutaneously inoculated tumors of C15A3 cells, which express CEACAM5, were visualized 
with high sensitivity. In the orthotopic pancreatic model, C1P83-conjugates can be applied for 
visualization of the orthotopic pancreatic tumor. Results of ex vivo were comparable to those 
obtained in vivo. Overall, fluorescent conjugates of C1P83-IRDye800CW were sensitive for 
detection of pancreas cancer by targeting CEACAM5. 
In conclusion, fluorescent C1P83-IRDye800CW conjugates were sensitive and selective 
for NIR fluorescent detection of pancreatic cancer by targeting CEACAM5. The CEACAM5 
epitope GOLD 3 is a potential molecular target for NIR fluorescent molecular imaging. This 
NIR fluorescent imaging modality based on the monoclonal antibody of C1P83 is expected to 
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